Danske Bank A S Invests $24.84 Million in IDEXX Laboratories, Inc. $IDXX

Danske Bank A S purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, Holdings Channel reports. The firm purchased 47,185 shares of the company’s stock, valued at approximately $24,840,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IDXX. J.Safra Asset Management Corp acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at about $25,000. SHP Wealth Management purchased a new position in IDEXX Laboratories in the 4th quarter worth approximately $26,000. Elevation Wealth Partners LLC boosted its holdings in shares of IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after purchasing an additional 32 shares during the last quarter. Virtus Advisers LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Finally, WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $30,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $562.20 on Thursday. The firm has a 50 day simple moving average of $560.33 and a 200-day simple moving average of $577.89. The stock has a market cap of $44.29 billion, a price-to-earnings ratio of 39.54, a price-to-earnings-growth ratio of 2.95 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Citigroup boosted their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Barclays dropped their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. UBS Group raised their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $747.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.